212 related articles for article (PubMed ID: 8661812)
1. Value of somatostatin receptor scintigraphy for preoperative localization of carcinoids.
Kisker O; Weinel RJ; Geks J; Zacara F; Joseph K; Rothmund M
World J Surg; 1996 Feb; 20(2):162-7. PubMed ID: 8661812
[TBL] [Abstract][Full Text] [Related]
2. [Bronchial carcinoid tumor and scintigraphy of somatostatin receptors: detection of bone metastasis].
Banzo J; Abós MD; Prats E; García F; Freile E; Razola P; Escalera T
Rev Esp Med Nucl; 2001 Oct; 20(6):431-8. PubMed ID: 11578577
[TBL] [Abstract][Full Text] [Related]
3. [Primary and follow-up studies of patients with carcinoid metastases using indium 111 octreotide--rational use of Sandostatin].
Lipp RW; Hammer HF; Passath A; Dobnig H; Ramschak-Schwarzer S; Stiegler C; Leb G; Krejs GJ
Acta Med Austriaca; 1993; 20(1-2):42-4. PubMed ID: 8475679
[TBL] [Abstract][Full Text] [Related]
4. Scintigraphic detection of carcinoid tumors with a cost effectiveness analysis.
Dimitroulopoulos D; Xynopoulos D; Tsamakidis K; Paraskevas E; Zisimopoulos A; Andriotis E; Fotopoulou E; Kontis M; Paraskevas I
World J Gastroenterol; 2004 Dec; 10(24):3628-33. PubMed ID: 15534919
[TBL] [Abstract][Full Text] [Related]
5. Improved visualization of carcinoid liver metastases by indium-111 pentetreotide scintigraphy following treatment with cold somatostatin analogue.
Dörr U; Räth U; Sautter-Bihl ML; Guzman G; Bach D; Adrian HJ; Bihl H
Eur J Nucl Med; 1993 May; 20(5):431-3. PubMed ID: 8100192
[TBL] [Abstract][Full Text] [Related]
6. Experience with somatostatin receptor scintigraphy in the management of pulmonary carcinoid tumors.
Yellin A; Zwas ST; Rozenman J; Simansky DA; Goshen E
Isr Med Assoc J; 2005 Nov; 7(11):712-6. PubMed ID: 16308994
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin-receptor scintigraphy in the management of gastroenteropancreatic tumors.
Krausz Y; Bar-Ziv J; de Jong RB; Ish-Shalom S; Chisin R; Shibley N; Glaser B
Am J Gastroenterol; 1998 Jan; 93(1):66-70. PubMed ID: 9448177
[TBL] [Abstract][Full Text] [Related]
8. Metastatic carcinoid tumor imaged with CT and a radiolabeled somatostatin analog: a case report.
Lobrano MB; McCarthy K; Adams L; Neitzschman H
Am J Gastroenterol; 1997 Mar; 92(3):513-5. PubMed ID: 9068482
[TBL] [Abstract][Full Text] [Related]
9. Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: bone scintigraphy compared with somatostatin receptor scintigraphy.
Lebtahi R; Cadiot G; Delahaye N; Genin R; Daou D; Peker MC; Chosidow D; Faraggi M; Mignon M; Le Guludec D
J Nucl Med; 1999 Oct; 40(10):1602-8. PubMed ID: 10520698
[TBL] [Abstract][Full Text] [Related]
10. 111In-octreotide scintigraphy in endocrine tumors. Preliminary data.
Cremonini N; Furno A; Sforza A; Chiarini V; Graziano E; Zampa G; Turba E
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):116-20. PubMed ID: 9002767
[TBL] [Abstract][Full Text] [Related]
11. The value of somatostatin-receptor scintigraphy in newly diagnosed endocrine gastroenteropancreatic tumors.
Kisker O; Bartsch D; Weinel RJ; Joseph K; Welcke UH; Zaraca F; Rothmund M
J Am Coll Surg; 1997 May; 184(5):487-92. PubMed ID: 9145069
[TBL] [Abstract][Full Text] [Related]
12. Ability of somatostatin receptor scintigraphy to identify patients with gastric carcinoids: a prospective study.
Gibril F; Reynolds JC; Lubensky IA; Roy PK; Peghini PL; Doppman JL; Jensen RT
J Nucl Med; 2000 Oct; 41(10):1646-56. PubMed ID: 11037994
[TBL] [Abstract][Full Text] [Related]
13. In-111 octreotide scan in a case of a neuroendocrine tumor of unknown origin.
Fuster D; Navasa M; Pons F; Vidal-Sicart S; Mateos JJ; Lomeña F; Rodes J; Herranz R
Clin Nucl Med; 1999 Dec; 24(12):955-8. PubMed ID: 10595476
[TBL] [Abstract][Full Text] [Related]
14. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors.
Lebtahi R; Cadiot G; Sarda L; Daou D; Faraggi M; Petegnief Y; Mignon M; le Guludec D
J Nucl Med; 1997 Jun; 38(6):853-8. PubMed ID: 9189129
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin receptor scintigraphy with 111In-octreotide in pulmonary carcinoid tumours correlated with pathological and 18FDG PET/CT findings.
Kuyumcu S; Adalet I; Sanli Y; Turkmen C; Ozkan ZG; Yilmazbayhan D
Ann Nucl Med; 2012 Nov; 26(9):689-97. PubMed ID: 22802007
[TBL] [Abstract][Full Text] [Related]
16. Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours.
Gotthardt M; Béhé MP; Grass J; Bauhofer A; Rinke A; Schipper ML; Kalinowski M; Arnold R; Oyen WJ; Behr TM
Endocr Relat Cancer; 2006 Dec; 13(4):1203-11. PubMed ID: 17158765
[TBL] [Abstract][Full Text] [Related]
17. [The scintigraphy of somatostatin receptors in the carcinoid tumor].
Banzo J; Abós MD; Prats E; Delgado M; Razola P; García S; Gomollón F; García F
Rev Esp Med Nucl; 2001 Feb; 20(1):11-8. PubMed ID: 11181324
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin analogue scintigraphy in carcinoid tumours.
Kwekkeboom DJ; Krenning EP; Bakker WH; Oei HY; Kooij PP; Lamberts SW
Eur J Nucl Med; 1993 Apr; 20(4):283-92. PubMed ID: 8491220
[TBL] [Abstract][Full Text] [Related]
19. In-111 DTPA octreotide scintigraphy and intraoperative gamma probe detection in the diagnosis and treatment of residual lymph node metastases of a rectal carcinoid tumor.
Banzo J; Vidal-Sicat S; Prats E; Galofré G; Razola P; Mañé S; Ubieto MA; Abós MD
Clin Nucl Med; 2005 May; 30(5):308-11. PubMed ID: 15827397
[TBL] [Abstract][Full Text] [Related]
20. [Somatostatin receptor scintigraphy. A new imaging procedure for the specific demonstration of carcinoids of the small intestine].
Dörr U; Räth U; Schürmann G; Höring E; Bach D; Wurm K; Scholz M; Adrian HJ; Bihl H
Rofo; 1993 Jan; 158(1):67-73. PubMed ID: 8425079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
